Literature DB >> 1707562

Effects of in vivo treatment with FK506 on natural killer cells in rats.

P M Markus1, M R Van den Brink, B A Luchs, J J Fung, T E Starzl, J C Hiserodt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1707562      PMCID： PMC2963998          DOI： 10.1097/00007890-199104000-00037

Source DB:  PubMed          Journal:  Transplantation        ISSN： 0041-1337            Impact factor:   4.939


× No keyword cloud information.
  6 in total

1.  Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine.

Authors:  N Murase; S Todo; P H Lee; H S Lai; F Chapman; M A Nalesnik; L Makowka; T E Starzl
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

2.  FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro.

Authors:  T Kino; H Hatanaka; S Miyata; N Inamura; M Nishiyama; T Yajima; T Goto; M Okuhara; M Kohsaka; H Aoki
Journal:  J Antibiot (Tokyo)       Date:  1987-09       Impact factor: 2.649

3.  Natural killer cell activity and antibody-dependent cellular cytotoxicity in patients under various immunosuppressive regimens.

Authors:  C Müller; G Schernthaner; J Kovarik; W Kalinowska; C C Zielinski
Journal:  Clin Immunol Immunopathol       Date:  1987-07

4.  Changes in immunological parameters after conversion from cyclosporine A to azathioprine in renal transplant recipients.

Authors:  D J Versluis; A M Bijma; L M Vaessen; W Weimar
Journal:  Int J Immunopharmacol       Date:  1989

5.  Natural killer cell activity in renal transplant recipients receiving cyclosporine.

Authors:  X E Gui; C R Rinaldo; M Ho
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

Review 6.  Biology of natural killer cells.

Authors:  G Trinchieri
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543
  6 in total
  7 in total

1.  A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine.

Authors:  J Fung; K Abu-Elmagd; A Jain; R Gordon; A Tzakis; S Todo; S Takaya; M Alessiani; A Demetris; O Bronster
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

2.  Studies on mechanisms of augmentation of liver regeneration by cyclosporine and FK 506.

Authors:  A Francavilla; T E Starzl; M Barone; Q H Zeng; K A Porter; A Zeevi; P M Markus; M R van den Brink; S Todo
Journal:  Hepatology       Date:  1991-07       Impact factor: 17.425

3.  Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease.

Authors:  S Todo; A J Demetris; D Van Thiel; L Teperman; J J Fung; T E Starzl
Journal:  Hepatology       Date:  1991-04       Impact factor: 17.425

4.  The in vivo effect of hepatotrophic factors augmenter of liver regeneration, hepatocyte growth factor, and insulin-like growth factor-II on liver natural killer cell functions.

Authors:  A Francavilla; N L Vujanovic; L Polimeno; A Azzarone; A Iacobellis; A Deleo; M Hagiya; T L Whiteside; T E Starzl
Journal:  Hepatology       Date:  1997-02       Impact factor: 17.425

Review 5.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Authors:  D H Peters; A Fitton; G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

6.  Rapamycin, but not cyclosporine or FK506, alters natural killer cell function.

Authors:  Lu-En Wai; Masato Fujiki; Saori Takeda; Olivia M Martinez; Sheri M Krams
Journal:  Transplantation       Date:  2008-01-15       Impact factor: 4.939

7.  Teratocarcinomas Arising from Allogeneic Induced Pluripotent Stem Cell-Derived Cardiac Tissue Constructs Provoked Host Immune Rejection in Mice.

Authors:  Ai Kawamura; Shigeru Miyagawa; Satsuki Fukushima; Takuji Kawamura; Noriyuki Kashiyama; Emiko Ito; Tadashi Watabe; Shigeo Masuda; Koichi Toda; Jun Hatazawa; Eiichi Morii; Yoshiki Sawa
Journal:  Sci Rep       Date:  2016-01-14       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.